Matching articles for "FEIBA"
Issue 1746 · January 19, 2026 Free
In Brief: Andexanet alfa (Andexxa) Withdrawn

Andexanet alfa ( Andexxa – AstraZeneca), which received accelerated approval from the FDA in 2018 for urgent reversal of the anticoagulant effect of the direct factor Xa inhibitors apixaban (Eliquis) and…

Med Lett Drugs Ther. 2026 Jan 19; 68(1746):16 doi:10.58347/tml.2026.1746f
Andexanet alfa ( Andexxa – AstraZeneca), which received accelerated approval from the FDA in 2018 for urgent reversal of the anticoagulant effect of the direct factor Xa inhibitors apixaban (Eliquis) and rivaroxaban (Xarelto) , has voluntarily been withdrawn from the market. Andexxa was the only drug FDA-approved for this indication in the US.